Israeli startup to use AI to transform antibody discovery, design
"The launch of CombinAble heralds a shift in the approach to targeted antibody design by leveraging AI to optimize and expedite the discovery process," said Mati Gill, CEO of AION Labs.
AI (Artificial Intelligence) letters and robot hand miniature in this illustration taken, June 23, 2023.(photo credit: REUTERS/DADO RUVIC/ILLUSTRATION/FILE PHOTO)ByMAAYAN JAFFE-HOFFMAN